Related Experiment Video
Updated: Oct 25, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Oxoisoaporphine Half-Sandwich Osmium(II) Derivative: A Catalytic Trigger for Innate Tumor Chemoimmunotherapy
Liang-Mei Yang1, Matthew S Levine2, Feng-Yang Wang3
1School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin541004, China.
Abstract:
Chemoimmunotherapy, particularly strategies that induce a tumor specific antitumor immune response, has emerged as a promising approach to improved cancer treatment. Nonetheless, only a limited number of drugs can successfully stimulate an antitumor immune response in vivo. Recent studies have highlighted the potential of metal-based anticancer agents in chemoimmunotherapy. Herein, we report a half-sandwich osmium(II) complex, Os-1, which acts as a catalyst for H2O2 generation through autocatalytic hydride transfer from coenzyme NADH to oxygen. Sustained H2O2 self-supply generation disrupts tumor redox homeostasis and induces DNA damage, leading to the activation of the cGAS-STING signaling pathway. Os-1 demonstrates potent cytotoxicity in vitro and elicits a robust antitumor immune response in vivo. Furthermore, Os-1 exhibits a synergistic antitumor growth effect when combined with a PD-1 inhibitor. To the best of our knowledge, this study is the first to describe the rational design of a small-molecule metal catalyst that provides for the in situ generation of H2O2 in cancer cells, thus overcoming the exogenous-additive bottleneck of oxidative therapy. This self-sufficient system not only promotes oxidative damage but also activates the cGAS-STING pathway, thereby integrating synergistically oxidative and immunotherapeutic actions.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
